The results showed that about 27.6% of patients with HR+/HER2−, 5.2% of patients with HR+/HER2+, 1.6% of patients with HR-/HER2+, 3.2% of patients with HR-/HER2− only had bone metastasis. This evidence concerns the gene HR and bone metastasis.